Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lihua E

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Cancer Research|July 19, 2017
CTLA4 Promotes Tyk2-STAT3-Dependent B-cell OncogenicityAndreas Herrmann, Christoph Lahtz, Toshikage Nagao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2015
CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T CellsXiuli Wang, ChingLam W Wong, Ryan Urak, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialMatthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
British Journal of Haematology|May 26, 2024
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphomaTamer Othman, John H Baird, Stacy Pak, et al.
Blood Cancer Journal|October 13, 2023
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myelomaSurbhi Sidana, Hitomi Hosoya, Alexandria Jensen, et al.
British Journal of Haematology|January 1, 2019
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trialLihua E Budde, David Wu, Daniel B Martin, et al.
Blood|March 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphomaJames K Godfrey, Lei Gao, Geoffrey Shouse, et al.
Blood|February 7, 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBrian G Till, Michael C Jensen, Jinjuan Wang, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Cancer Research|July 19, 2017
CTLA4 Promotes Tyk2-STAT3-Dependent B-cell OncogenicityAndreas Herrmann, Christoph Lahtz, Toshikage Nagao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2015
CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T CellsXiuli Wang, ChingLam W Wong, Ryan Urak, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 9, 2024
Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialMatthew Matasar, Nancy L Bartlett, Mazyar Shadman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantationLihua E Budde, Katherine A Guthrie, Brian G Till, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L Locke, Sattva S Neelapu, Nancy L Bartlett, et al.
British Journal of Haematology|May 26, 2024
Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphomaTamer Othman, John H Baird, Stacy Pak, et al.
Blood Cancer Journal|October 13, 2023
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myelomaSurbhi Sidana, Hitomi Hosoya, Alexandria Jensen, et al.
British Journal of Haematology|January 1, 2019
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trialLihua E Budde, David Wu, Daniel B Martin, et al.
Blood|March 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphomaJames K Godfrey, Lei Gao, Geoffrey Shouse, et al.
Blood|February 7, 2012
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBrian G Till, Michael C Jensen, Jinjuan Wang, et al.
Pageof 8